Finerenone (BAY 94-8862) is a potent, selective, orally available mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM.
Finerenone (BAY 94-8862) displays excellent selectivity (>500-fold) versus GR, AR, and PR, also shows no L type Ca2+ channel activity.
Finerenone (BAY 94-8862) elicits a significant and dose-dependent increase in the urinary sodium/potassium ratio in vivo, with a MED of 0.3 mg kg1 p.o.
Finerenone (BAY 94-8862) exhibits three- to tenfold greater potency and higher efficacy in acute rat natriuresis model compared with eplerenone, demonstrates potential for the treatment of chronic heart failure (CHF).
